Events

SAN DIEGO, May 20, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis and…

SAN DIEGO, February 1, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis, psoriasis…

Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patients Pipeline molecule to treat T cell mediated autoimmune diseases – San Diego, CA, USA, and Munich,…

SAN DIEGO, Dec 11, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the Phase 1b clinical trial in autoimmune…

SAN DIEGO, Sept 25, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the Phase 1b clinical trial in autoimmune…

SAN DIEGO, May 9, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the Phase 1b clinical trial in autoimmune…

SAN DIEGO, February 9, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.

SAN DIEGO, February 1, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis.

SAN DIEGO, December 1, 2022 – Meet Antonius Schuh, Ph.D. (CEO), and Steve Zaniboni (CFO) for an update on selectION’s clinical work in atopic dermatitis.

SAN DIEGO, October 1, 2022 – Meet Antonius Schuh, Ph.D. (CEO), and Andreas Klostermann, Ph.D. (CSO) for an update on selectION’s best-in-class ion channel blockers and the status of the…